Eli Lilly and Company Retevmo shows major reduction in cancer recurrence risk trial
Eli Lilly's Retevmo cut cancer recurrence or death risk by 83% in the Phase 3 LIBRETTO-432 trial of 151 NSCLC patients. 24-month EFS hit 92%
seen from United States

seen from Malaysia
seen from China
seen from Netherlands
seen from United States

seen from Malaysia

seen from Malaysia
seen from Canada

seen from Brazil

seen from United States
seen from Azerbaijan

seen from United States

seen from Spain
seen from United States

seen from Israel
seen from United States
seen from Canada
seen from Spain
seen from United States

seen from Israel
Eli Lilly and Company Retevmo shows major reduction in cancer recurrence risk trial
Eli Lilly's Retevmo cut cancer recurrence or death risk by 83% in the Phase 3 LIBRETTO-432 trial of 151 NSCLC patients. 24-month EFS hit 92%